AbbVie licenses novel bispecific antibody from RemeGen for $5bn
New deal strengthens AbbVie's oncology portfolio, adding a new class of cancer therapeutics to its inventory.
List view / Grid view
New deal strengthens AbbVie's oncology portfolio, adding a new class of cancer therapeutics to its inventory.
The FDA has granted ODD to Telitacicept, produced by RemeGen, for the treatment of myasthenia gravis.